This page collects WhisperX intelligence signals tagged #biopharmaceutical. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Protagenic Therapeutics, Inc. has formally notified the U.S. Securities and Exchange Commission of a significant change in its executive leadership. The company's recent 8-K filing, submitted on April 7, 2026, discloses a departure under Item 5.02, which governs the exit of directors or certain officers. This mandatory...
Day One Biopharmaceuticals, Inc. has filed an SEC Form 8-K dated April 23, 2026, triggering a cascade of material corporate event disclosures that collectively signal a significant corporate restructuring. The filing activates nine distinct regulatory provisions, including termination of a material definitive agreement...
Nektar Therapeutics has submitted an 8-K filing with the SEC that signals significant corporate activity. The biopharmaceutical company reported the entry into a material definitive agreement under Item 1.01, alongside simultaneous leadership transitions flagged under Item 5.02. The combination of a material agreement ...